Search results

Source:

US Food and Drug Administration - FDA (Remove filter)

02 December 2021

Coronavirus (COVID-19) Update

Type:

Prescribing and Technical Information (Remove filter)

Source:

US Food and Drug Administration - FDA (Remove filter)

01 December 2021

FDA has released the Artificial Intelligence/Machine Learning- Based Software as a Medical Device Action Plan which outlines FDA’s next steps towards advancing practical oversight for these issues.

Type:

Prescribing and Technical Information (Remove filter)

Source:

US Food and Drug Administration - FDA (Remove filter)

01 November 2021

The U.S. Food and Drug Administration has conditionally approved Laverdia-CA1 (verdinexor), the first oral tablet for treatment of canine lymphoma.

Type:

Prescribing and Technical Information (Remove filter)

Source:

US Food and Drug Administration - FDA (Remove filter)

02 September 2021

Today, the FDA issued an emergency use authorization for two monoclonal antibodies administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients who are at...

Type:

Prescribing and Technical Information (Remove filter)

Source:

US Food and Drug Administration - FDA (Remove filter)

02 September 2021

Coronavirus (COVID-19) Update

Type:

Prescribing and Technical Information (Remove filter)

Source:

US Food and Drug Administration - FDA (Remove filter)

02 August 2021

FDA provides resource for clinical field studies investigating Animal Cells, Tissues, and Cell- and Tissue-Based Products (ACTPs) providing animal owners, veterinarians, researchers and the public...

Type:

Prescribing and Technical Information (Remove filter)

Source:

US Food and Drug Administration - FDA (Remove filter)

01 August 2021

FDA is alerting clinical laboratory staff and health care providers that it is monitoring the impact of viral mutations, including the variant from the United Kingdom, the B.1.1.7 variant, on...

Type:

Prescribing and Technical Information (Remove filter)

Source:

US Food and Drug Administration - FDA (Remove filter)

01 August 2021

Coronavirus (COVID-19) Update: January 8, 2021

Type:

Prescribing and Technical Information (Remove filter)

Source:

US Food and Drug Administration - FDA (Remove filter)

02 May 2021

FDA authorizes marketing for the eXiteOSA, a device intended to reduce snoring and mild obstructive sleep apnea in patients 18 years and older

Type:

Prescribing and Technical Information (Remove filter)

Source:

US Food and Drug Administration - FDA (Remove filter)

02 May 2021

Coronavirus (COVID-19) Update

Type:

Prescribing and Technical Information (Remove filter)